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Abstract 
I was asked to examine the presence of hyponatremia (<130 mEq/L) in older patients (>65 years) taking Selective Serotonin Reuptake 
Inhibitors (SSRIs) at Moses Cone Hospital. The presence of hyponatremia in older patients using SSRIs indicates potentially 
inappropriate use according to the STOPP (Screening Tool of Older Persons’ Potentially Inappropriate Prescriptions) and START 
(Screening Tool to Alert Doctors to Right Treatment) criteria6. This study was done to assess possible risk factors for potentially 
inappropriate use of SSRIs by older patients at Moses Cone Hospital. Data collected included the patient’s sex, age, sodium level, and 
the date the sodium level was drawn. Data also included the specific SSRI and the starting date for the SSRI. The study showed no 
relationship between age, sex, SSRI prescribed and hyponatremia. However, patients that were prescribed an SSRI for less than a year 
were more at risk for hyponatremia. Therefore, in order to minimize the risk of hyponatremia, additional monitoring may need to be 
added at SSRI initiation, three months, six months, and one year, especially in patients with other medications that may lower sodium 
levels. 
 
 
Introduction 
In the United States, the majority of older adults have 
multimorbidity, which is the coexistence of multiple chronic 
conditions. According to Medicare claims data from 2008, 
67% of all beneficiaries had two or more chronic conditions. 
One of the consequences of multimorbidity is the use of 
multiple medications. As a result, nearly 90% of Medicare 
beneficiaries were on at least one prescription medication 
and 46% of beneficiaries were on five or more medications. 
Using multiple medications increases the number of 
medication combinations, which can increase the risk of 
adverse drug reactions and drug-drug interactions2. 
Furthermore, polypharmacy is associated with an increased 
rate of rehospitalization. The use of seven or more drugs was 
associated with higher rates of unplanned rehospitalizations. 
Older adults might be victims of a “prescribing cascade” that 
might include inappropriate medications, thus leading to an 
increase in rehospitalization8. Adverse drug reactions are 
prevalent in older adults because typically they are using 
multiple drug regimens and because an increase in age leads 
to changes in their pharmacokinetics and pharmacodynamics 
(Mirko Petrovic, Adverse Drug Reactions in Older People). 
Hepatic blood flow decreases by 40%, thus decreasing the 
amount of first-pass metabolism that occurs in the liver7. This 
may result in the need of lowered dosing in medications like 
warfarin, benzodiazepines, and opiates5. Serum proteins, 
which are capable of binding to drug, decrease due to 
malnutrition and dietary changes, leading to an increase in 
unbound drug. This may increase the effects of the drug and 
lead to unintended consequences. Distribution of drugs  
 
 
Corresponding author: Sonya Anderson, PharmD candidate 
University of North Carolina Eshelman School of Pharmacy 
sonyaanderson1993@gmail.com  
 
within the body is also changed because of a decrease in ratio 
of lean body weight to body fat. Finally, for the ages 60-60, 
around 22% have some form of chronic kidney disease (CKD), 
the majority being Stage 3. For the ages 70 and above, 
around 47% have some form of CKD, the majority being Stage 
31. This means that the process of drug metabolism by the 
kidney is slowed and the drug will be present in the body for 
longer periods of time. However, many of these adverse drug 
events are preventable. In an ambulatory setting, adverse 
drug events were preventable in around 28% of older adults3. 
One way to avoid these events is by utilizing the STOPP 
(Screening Tool of Older Persons’ Potentially Inappropriate 
Prescriptions), and START (Screening Tool to Alert Doctors to 
Right Treatment) criteria6. The STOPP criteria was used in this 
study to identify possible adverse events. Furthermore, the 
STOPP criteria was used instead of the Beers criteria because 
STOPP is thought to work better than Beers to identify meds 
that result in negative outcomes, like in hospital admission6. 
This can help in identifying medications that result in negative 
outcomes, like adverse events and hospital admissions6,7.  
 
One class of drugs the START STOPP criteria cautions about 
are SSRIs. They are potentially inappropriate to use in older 
adults (>65 years) per STOPP if they have a history of sodium 
<130 mEq/L (mmol/L) within the past two months6,7. The 
clinical concern with SSRIs is potential for hyponatremia. In 
order to prevent adverse drug events, SSRIs should be 
tapered and discontinued in those that meet these 
criterion6,7. The purpose of the study was to assess what 
factors other than concomitant medications put older adults 
more at risk for inappropriate use of SSRIs. Concomitant 
medications were not addressed because the purpose of the 
study was only to look at SSRI medications in relation to 
hyponatremia according to the STOPP criteria. While there 
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are other STOPP criteria for other medications, the only 
STOPP criteria where hyponatremia is a clinical concern is 
with SSRIs.   
 
Methods 
To assess what factors put older patients more at risk for 
inappropriate use at Moses Cone Hospital, a report was ran 
on admitted patients that were on one or more SSRIs from 
June 18th to June 22nd, 2016. A one week period was used to 
ensure enough patients meeting the STOPP criteria could be 
analyzed. Inclusion criteria for the study included patients 
ages 65 years old or older, currently admitted, and on one or 
more SSRI for two months or greater. Absolute risk was 
addressed in this study. Patients could have just been newly 
admitted or been admitted for a longer period of time. 
Before admission at Moses Cone Hospital, medication 
reconciliation was done to ensure their medication list was up 
to date. An audit trail was ran in the report to make sure the 
patient had been taking the SSRI for two months or greater. 
The study only investigated if they were taking an SSRI for 
two months or longer, not if the SSRI was working for them. 
Moses Cone Hospital represents populations from both the 
rural and urban settings in Greensboro, North Carolina. From 
the electronic health record data extracted, patients were 
identified and data was collected on age, sex, the SSRI they 
were taking, the start date of their SSRI, their sodium levels, 
and the date the sodium levels drawn. The sodium levels 
analyzed were sodium levels taken within two months of the 
study time period. Having a sodium level below 130 mmol/L 
meant that the SSRI(s) may require closer monitoring or that 
perhaps it was inappropriate. Having a sodium level between 
131 and 134 mmol/L meant they were at an elevated risk for 
hyponatremia and the SSRI(s) may require closer monitoring 
especially if combined with other medications that lower 
sodium like diuretics. Having a sodium level above 135 
mmol/L meant that the SSRI(s) most likely did not cause 
hyponatremia in this patient and may be appropriate. 
Comorbidities were address, and there were no comorbidities 
in patients that affected sodium levels. Out of 257 patients, 
there were a total of 69 patients that were included in this 
study and were included only once if their admission was for 
longer than one day. The data was analyzed for possible 
correlations between the patient’s sex, age, SSRI taken, SSRI 
start date, and their sodium level. 
To understand more about the patients selected for this 
study, we chose to break down the data into age groups. The 
six different groups were split into 5 year intervals as follows: 
65-69, 70-74, 75-79, 80-84, 85-89, and 90-94 years old.   
 
Results 
Patient Demographics  
The average age of patients in this study was 76.9 years old, 
and the age distribution can be seen in Table 1. With respect 
to patient gender, 46 were female (66.7%) and 23 were male 
(33.3%). There were 5 patients on two SSRIs (7.2%), while 64 
patients received only one SSRI (92.8%). Patients were 
prescribed a variety of SSRIs with three representing a vast 
majority (Table 2).  
 
The length of therapy patients had been on SSRIs differed: 55 
patients were on an SSRI for less than one year, 11 patients 
had been on an SSRI for 1-3 years, and 3 patients for more 
than one year (see Figure 1).  
 
Lastly, patients had varying sodium levels. The lowest sodium 
level that the patient had in two months was recorded. 9 
patients had a sodium level below 130 mmol/L, 12 patients 
had a sodium level between 131 and 134 mmol/L, and 48 
patients had sodium levels above 135 mmol/L (see Figure 2). 
Hyponatremia is defined as sodium levels below 135 mmol/L, 
so 21 patients were hyponatremic (30.4% of patients). In 
total, SSRI prescriptions were even across age groups; 
females were prescribed more SSRIs than males; most 
patients were on only one SSRI; Escitalopram and Sertraline 
were prescribed most often; most patients were on their SSRI 
for less than one year. 
 
Patients at Risk for Inappropriate Use and Patients with 
Inappropriate Use 
The next step was to look at what factors other than 
concomitant medications may have contributed to a decrease 
in sodium levels. Factors analyzed included patient sex, age, 
duration of SSRI use, and the SSRI used. Patients that were at 
risk for hyponatremia and potentially inappropriate use as 
well as patients with hyponatremia and potentially 
inappropriate use were reviewed to identify a possible 
correlation between one of these factors and their 
hyponatremia. Out of 21 patients with hyponatremia, 6 were 
male (28.6% of patients) and 15 were female (71.4% of 
patients). The age breakdown is shown in Table 3.  
 
The duration of therapy for the SSRI was reviewed among 
patients with hyponatremia and 17 patients had been 
receiving the SSRI for less than one year, 3 patients had been 
on the SSRI between one and three years, and only 1 patient 
had been receiving the SSRI for more than three years (see 
Figure 3).  
 
The SSRIs prescribed among patients with hyponatremia are 
shown in Table 4. Only one patient had been using more than 
one SSRI. There appeared to be a trend with more female 
patients than male patients that had hyponatremia. But this 
may be because there were more females prescribed SSRIs 
than males. Out of the 46 older adult females that were 
prescribed SSRIs, 15 had hyponatremia, meaning that 32.6% 
of those prescribed developed hyponatremia. Out of the 23 
older adult males that were prescribed SSRIs, 6 had 
hyponatremia, meaning that 26% of those prescribed 
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developed hyponatremia. A Z-test was run with a significance 
level of 0.05, leading to a p-value of 0.286, meaning the 
difference was not significant between the two gender 
populations. There seemed to be no association between 
patient age and risk for hyponatremia, as this attribute 
showed a fairly even distribution between the different age 
groups. There was no association between the specific SSRI 
prescribed and a risk for hyponatremia. It appeared that 
more patients that had been on their SSRI for less than one 
year seemed to have hyponatremia. Out of the 55 adults 
prescribed an SSRI for less than a year, 17 adults had 
hyponatremia, meaning that 30.9% of adults prescribed an 
SSRI for less than a year developed hyponatremia. Out of 11 
adults prescribed an SSRI for one to three years, 3 adults had 
hyponatremia, meaning that 27.3% of adults prescribed an 
SSRI for one to three years developed hyponatremia. Out of 3 
adults prescribed an SSRI for over three years, 1 adult had 
hyponatremia, meaning that 1.4% of adults prescribed an 
SSRI for over three years developed hyponatremia. A Z-test 
with a significance level of 0.05 was ran to compare adults 
prescribed an SSRI for less than a year and adults prescribed 
an SSRI for between one to three years. The result was not 
significant with a p-value of 0.412. A Z-test with a significance 
level of 0.05 was ran to compare adults prescribed an SSRI for 
less than a year and adults prescribed an SSRI for over three 
years. The result was not significant with a p-value of 0.472. 
Thus for risk of hyponatremia, the risk was not significant 
between length of time the SSRI was prescribed.  
 
The last step was to look at what was causing the decrease in 
sodium levels in patients that had hyponatremia and 
potentially inappropriate use of their SSRI. Again, the factors 
analyzed included patient sex, age, duration of SSRI use, and 
the SSRI used. Out of nine patients with inappropriate SSRI 
use, three were male (33.3% of patients) and six were female 
(66.7% of patients).  
 
The age breakdown is shown in Table 5. Of these patients, 
eight had been on the SSRI for less than one year, 1 patient 
received their SSRI between one and three years, and no 
patients in this group had been receiving the SSRI for more 
than three years (see Figure 4). Only one patient had been 
receiving more than one SSRI and those used are shown in 
Table 6. More female patients were affected by 
hyponatremia than male patients. However, out of 46 
females, sex females had inappropriate SSRI use, meaning 
that 13% of females had inappropriate SSRI use. Out of 23 
males, three males had inappropriate SSRI use, meaning that 
13% of males had inappropriate SSRI use. A Z-test was ran 
with a significance level of 0.05, leading to a p-value of 0.5, 
thus there was no significant difference between the genders 
with respect to inappropriate SSRI use. There was no 
association between patient age and risk for hyponatremia, 
as this attribute showed a fairly even distribution between 
the different age groups. Patients that had inappropriate use 
of SSRIs also had Escitalopram and Sertraline due to higher 
prescription rates, thus was not significant. Much like the 
previous grouping of patients with hyponatremia, this 
grouping of patients with inappropriate SSRI use had more 
patients with hyponatremia if they had been taking their SSRI 
for less than one year. Of these patients 88.9% had been 
using it for less than one year. Out of 55 patients that were 
prescribed an SSRI for less than a year, eight had 
inappropriate use of the SSRI prescribed, meaning 14.5% of 
patients prescribed an SSRI for less than a year had 
inappropriate use. Out of 11 patients that were prescribed an 
SSRI for between one to three years, one had inappropriate 
use of the SSRI prescribed, meaning 9.1% of patients 
prescribed an SSRI for one to three years had inappropriate 
use. Out of three patients that were prescribed an SSRI for 
more than three years, zero had inappropriate use of the 
SSRI. A Z-test with a significance level of 0.05 was ran to 
compare patients with inappropriate use of SSRI that had 
been prescribed an SSRI for less than a year and those that 
had been prescribed an SSRI for one to three years. This 
resulted in a p-value of 0.298, thus not significant. A Z-test 
with a significance level of 0.05 was ran to compare patients 
with inappropriate use of SSRI that had been prescribed an 
SSRI for less than a year and those that had been prescribed 
an SSRI for over three years. This resulted in a p-value of 
0.001, thus significant. This may indicate a need for closer 
monitoring with new starts of SSRIs in the older adult 
population. It may be prudent to obtain basic chemistry 
bloodwork on initiation, three months, six months, and one 
year to evaluate for hyponatremia.  
 
Conclusion 
The purpose of this study was to assess what risk factors put 
older adults (> 65 years old) at risk for inappropriate use of 
their prescribed SSRI. Inappropriate used was defined as 
having a sodium level below 130 mmol/L. Per STOPP criteria, 
if an older adult patient has an instance of a sodium level 
below 130 mmol/L while on an SSRI, the SSRI should be 
tapered and discontinued. Patients were identified and 
information on age, sex, the SSRI they were taking, the start 
date of their SSRI, their sodium levels, and date the sodium 
levels were drawn. The overall findings indicated that there 
was no relationship between age, sex, the SSRI they were 
taking and their sodium levels. However, there was a 
significant relationship with respect to the start date of the 
SSRI and the sodium levels. Those that had been taking an 
SSRI for less than a year were more prone to hyponatremia 
than those that had be on an SSRI for more than three years. 
While there was not a significant difference in risk for 
hyponatremia between those that had been taking an SSRI 
for less than a year and those that had been taking an SSRI 
for one to three years, there were still more instances of 
hyponatremia in those taking an SSRI for less than a year.  
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In order avoid inappropriate use of SSRIs and possible 
adverse events in older adults, there may need to be closer 
monitoring with new starts of SSRIs in the older adult 
population. It may be prudent to obtain basic chemistry 
bloodwork on initiation, three months, six months, and one 
year to evaluate for hyponatremia. This is because there was 
a significant difference in sodium levels between those that 
were using an SSRI for less than a year and those that were 
using an SSRI for over three years. Closer monitoring is need 
in the first year to ensure that the SSRI they are prescribed is 
appropriate for them. Closer monitoring would indicate early 
on whether a switch to a different anti-depressant would be 
more suitable, thus preventing possible adverse events and 
help decrease the patient’s overall health costs4. 
 
Limitations of this study include a small sample size of 
patients, use of only one hospital setting, limited review to 
only SSRIs and not other medications that may have 
contributed to hyponatremia. Larger studies may be required 
to delineate between length of SSRI use and increased risk, 
however, based on the trend the data presents, it appears 
that those that had been taking the SSRI for less than a year 
had a higher risk of developing hyponatremia. Additional 
sodium level monitoring for those on SSRIs has important 
implications for both hospital and community pharmacist. For 
hospital pharmacists, additional monitoring allows a chance 
to ensure the SSRI will not result in hyponatremia, thus 
ensuring the SSRI is appropriate. If they have additional 
monitoring done upon initiation of the SSRI and when 
initiating medications that might potentiate the SSRI’s effects, 
hospital pharmacists will see potentially see less adverse drug 
events resulting from SSRI use. Depending on if the hospital 
pharmacist follows up the result, this could provide them 
with additional consoling time. They could also check in with 
the patient to ensure that the SSRI is working to control their 
symptoms after a month. If not, they could recommend that 
the doctor switch or add an additional agent to better control 
their symptoms. It will also give community pharmacists a 
chance to provide additional consoling points when SSRIs are 
initiated. If additional monitoring in the first year of SSRI use 
is started, community pharmacists could follow up with them 
on their results. If their results are abnormal, they would be 
able to contact their primary care provider to alert them that 
the patient’s SSRI may potentially be inappropriate. 
Additional monitoring would also have important implications 
in the healthcare system by preventing adverse drug events 
that increase overall healthcare costs.  
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Table 1. Age breakdown of all patients (n=69). 
Age Number of Patients %
65-69 13 18.8
70-74 16 23.2
75-79 15 21.7
80-84 15 21.7
85-89 6 8.7
90-94 4 5.8
SSRI Number of Patients
Citalopram 9
Duloxetine 5
Mirtazapine 5
Venlafaxine 3
Venlafaxine XR 1
Amitriptyline 4
Escitalopram 15
Paroxetine 5
Fluoxetine 1
Nefazodone 1
Bupropion 6
Sertraline 19
Table 2. SSRI breakdown of all patients. 
Figure 1. SSRI use breakdown of all patients. 
Figure 2. Sodium level breakdown of all patients. 
4.3% 
15.9% 
79.7%
 
13% 
17.4% 
69.6% 
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Table 3. Age breakdown of patients  
with hyponatremia (n=21). 
Age Number of Patients %
65-69 5 23.8
70-74 6 28.6
75-79 3 14.3
80-84 4 19
85-89 2 9.5
90-94 1 4.8
Figure 3. SSRI use breakdown of patients 
 with hyponatremia. 
Table 4. SSRI breakdown of patients  
with hyponatremia. 
SSRI Number of Patients
Citalopram 4
Duloxetine 2
Venlafaxine XR 1
Amitriptyline 1
Escitalopram 5
Paroxetine 2
Fluoxetine 1
Nefazodone 1
Bupropion 1
Sertraline 4
Table 5. Age breakdown of patients  
with inappropriate SSRI use (n=9). 
Age Number of Patients %
65-69 3 33.3
70-74 2 22.2
75-79 1 11.1
80-84 3 33.3
85-89 0 0
90-94 0 0
4.7% 
14.3% 
80.9% 
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Figure 4. SSRI use breakdown of patients 
 with inappropriate SSRI use. 
Table 6. SSRI breakdown of patients  
with inappropriate SSRI use. 
SSRI Number of Patients
Citalopram 1
Duloxetine 0
Venlafaxine XR 0
Amitriptyline 1
Escitalopram 3
Paroxetine 1
Fluoxetine 0
Nefazodone 1
Bupropion 1
Sertraline 2
88.9% 
11.1% 
